SIRT1 and metabolic dysfunction-associated steatotic liver disease: Moreover, at a preclinical level, Lico-A exhibited the ability to enhance the sirt1/AMPK pathway, thereby improving non-alcoholic fatty liver disease (NAFLD) [71].